Fig. 3

Palbociclib-mediated reduction in levels of phosphorylated proteins that are involved in mast cell activation. Western blots of total lysate samples from activated mast cells (see “Materials and methods”) demonstrating palbociclib treatment (0 μM, 10 μM, 20 μM, and 40 μM) inhibition of Lyn activation (a) and MAPK (p38, JNK, and ERK1/2) activation (b). c β-Hexosaminidase release from activated BLCs subjected to 1-h pretreatments (as experimentally indicated) prior to the challenge. d Western blot analysis of Lyn expression in RBL-2H3 cells transfected with siRNA-Lyn. e β-Hexosaminidase release from activated BLCs pretreated with siRNA-Lyn and palbociclib. f β-Hexosaminidase release from activated BLCs pretreated with signaling inhibitors (ERK inhibitor U0126, JNK inhibitor SP600125, and p38 inhibitor SB203580) for 1 h prior to the challenge